Cost effectiveness of total knee arthroplasty from a health care providers' perspective before and after introduction of an interdisciplinary clinical pathway - is investment always improvement? by Krummenauer, Frank et al.
RESEARCH ARTICLE Open Access
Cost effectiveness of total knee arthroplasty from
a health care providers’ perspective before and
after introduction of an interdisciplinary clinical
pathway - is investment always improvement?
Frank Krummenauer
1*, Klaus-Peter Guenther
2 and Stephan Kirschner
2
Abstract
Background: Total knee arthroplasty (TKA) is an effective, but also cost-intensive health care intervention for end
stage osteoarthritis. This investigation was designed to evaluate the cost-effectiveness of TKA before versus after
introduction of an interdisciplinary clinical pathway from a University Orthopedic Surgery Department’s cost
perspective as an interdisciplinary full service health care provider.
Methods: A prospective trial recruited two sequential cohorts of 132 and 128 consecutive patients, who were
interviewed by means of the WOMAC questionnaire. Direct process costs from the health care providers’
perspective were estimated according to the German DRG calculation framework. The health economic evaluation
was based on margiual cost-effectveness ratios (MCERs); an individual marginal cost effectiveness relation ≤ 100 €
per % WOMAC index increase was considered as primary endpoint of the confirmatory cohort comparison. The
interdisciplinary clinical pathway under consideration primarily consisted of a voluntary preoperative personal
briefing of patients concerning postoperatively expectable progess in health status and optimum use of walking
aids after surgery. All patients were supplied with written information on these topics, attendance of the personal
briefing also included preoperative training for postoperative mobilisation by the Department’s physiotherapeutic
staff.
Results: An individual marginal cost effectiveness relation ≤ 100 €/% WOMAC index increase was found in 38% of
the patients in the pre pathway implementation cohort versus in 30% of the post pathway implementation cohort
(Fisher p = 0.278). Both cohorts showed substantial improvement in WOMAC scores (39 versus 35% in median),
whereas the cohort did not differ significantly in the median WOMAC score before surgery (41% for the pre
pathway cohort versus 44% for the post pathway cohort). Despite a locally significant decrease in costs (4303
versus 4194 € in median), the individual cost/benefit relation became worse after introduction of the pathway: for
the first cohort the MCER was estimated 108 € per gained % WOMAC index increase (86 - 150 €/%) versus 118 €/%
WOMAC gain (93 - 173 €/%) in the second cohort after pathway implementation. In summary, the proposed critical
pathway for TKA could be shown to be significantly cost efficient, but not cost effective concerning functional
outcome, when the above individual marginal cost effectiveness criterion was concentrated on.
Conclusions: The introduction of an interdisciplinary clinical pathway does not necessarily improve patient related
outcomes. On the contrary, cost effectiveness from the health care providers’ perspective may even turn out
remarkably reduced in the setting considered here (functional outcome assessment after treatment by a full service
health care provider).
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Total knee replacement/arthroplasty (TKA) for end
stage osteoarthritis is a successful intervention to reduce
pain and improve function of the patients [1,2]; as a
consequence, in ageing populations the need for total
joint arthroplasty is rising, [3] in particular for TKA [4].
As a parallel development clinical pathways have been
increasingly considered over the past two decades to
improve the management of patients and to control for
the costs of medical treatment [5,6]. Different interven-
tions were reported over the last decades to control
costs in total joint arthroplasty. Implant standardisation
[7-9] and shortening hospital length [10,11] of stay were
most often used in clinical pathways.
A recent meta-analysis on the effects of clinical path-
ways for total joint arthroplasty in terms of length of
stay (LOS) as well as expectable changes in re-admission
rates reported complication profiles and costs [12].
Interestingly, the observed effects were not unambigu-
ous: no clinically relevant effects could be confirmed for
clinical pathways concerning the rate of discharge to
home when compared to standard care. On the other
hand, this meta-analysis could demonstrate pathways to
have beneficial effects on costs, LOS and complication
rates. Another recent meta-analysis of the effects of clin-
ical pathways, which was not limited to Orthopedic Sur-
gery, confirmed the positive effect on LOS in particular
for invasive procedures [13], although no effects were
found for re-admission rates and in-house complication
rates. A wide heterogenity between studies reporting
LOS data and costs in the context of critical pathway
implementation was reported.
The introduction of a clinical pathway does not repre-
sent a standardized intervention. By the time being,
there is only little research done on methods for the
evaluation of clinical pathways [14,15]. Although eco-
nomic process evaluation methods do offer ideas for
analysis of pathway implementations, their design and
analysis approach is hardly suitable for the health care
evaluation setting: one reason for this is the necessity to
simultaneously consider process quality and costs as
well as non-process (but rather patient-related) clinical
outcome quality indicators. To decide whether a clinical
p a t h w a yh a sap o s i t i v ee f f e c to nc o s t s ,i t sp u t a t i v e
improvement in terms of patient-related function and
quality of life has to be balanced against health care pro-
vider cost profiles [16].
The objective of the present study was to evaluate the
cost effectiveness of total knee arthroplasty (TKA) with
respect to the introduction of an interdisciplinary clini-
cal pathway from the health care providers’ perspective
under consideration of patient related (functional) out-
come indicators. Note that this investigation will not
focus on a reduction of the TKA patients’ indivdiual or
median length of stay as concentrated on by most recent
literature: when the investigation was designed for
implementation in an Orthopedic Surgery department,
it could be assumed, that this department already had
implemented standard processes achieving a somewhat
short median overall LOS in previous process optimiza-
tion steps. As a consequence the critical pathway under
consideration was designed to rather introduce patient-
related features such as preoperative information on
postoperatively expectable gain in health and mobility -
and thereby to address compliance-related issues rather
than the underlying health care process itself. Neverthe-
less, since introduction of these pathway components
had to be fully accomplished by the Orthopedic Surgery
Department “at its own costs”, the authors decided to
retain the Department’s perspective for the overall cost
effectiveness consideration of implementing the clincal
pathway.
Methods
The primary intention of this investigation was to derive
an estimate for the cost effectiveness of TKA before and
after introduction of an interdisciplinary clinical pathway
into clinical routine. For that purpose a prospective
sequential cohort observation with the aim of simulta-
neously estimating the process costs from a full service
(University Hospital) health care providers’ perspective
and the corresponding patient-related benefit of TKA
was implemented.
Study Design
This prospective cost effectiveness investigation com-
prised individual data of patients, who underwent unilat-
eral TKA at the Orthopedic Surgery Department of the
Dresden University Hospital (Germany) in 2006 and
2007. The Dresden University Hospital’s Orthopedic
Surgery Department consists of several clinical units,
among them a well-established hip and knee arthro-
plasty unit run by two highly experienced senior Ortho-
pedic surgeons (KPG and SK). The unit has direct
access to physiotherapeutic staff and facilities, and
thereby can enable to implement improvement con-
cenpts on patient care pathways immediately after iden-
tification in direct communication with local nursing
and physiotherapy staff.
A total of 260 patients with the clinical indication for
TKA were enrolled consecutively and asked for partici-
pation in this prospective health economic investigation.
After written informed consent patients underwent a
written interview by means of the WOMAC question-
naire one week before surgery. The interviews were
scheduled by a local study coordinator, who offered
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t h ep a t i e n t sw e r ei n v i t e df o rat h r e em o n t h sr e c a l lt o
undergo the same interview.
The overall cohort of 260 patients comprised two
sequentially recruited (sub) cohorts: a process documen-
tation of the clinical course within a first cohort of 132
patients was used to derive and then implement an
interdisciplinary clinical pathway on TKA; after a three
months period of confirming this pathway proposal
within clinical routine, a second independent cohort of
128 patients undergoing TKA was recruited and docu-
mented at the same hospital. The aim of this sequential
cohort design was to compare the cost/benefit relation
of TKA within one clinical health care provider unit
before and after introduction of an interdisciplinary clin-
ical pathway. Figure 1 summarizes the sequential cohort
design, which was ratified by the local Independent
Ethics Committee of the Medical Faculty of Dresden
Technical University by June 25
th 2005.
Surgical Procedure
The study population consisted of patients with pri-
mary or secondary osteoarthritis of the knee joint
stage 3 or 4 according to Kellgren. The patients were
routinely operated under tourniquet after admission of
perioperative antibiotic prophylaxis in a laminar air-
flow room. Through a straight skin incision and a
medial parapatellar approach a cemented Natural Knee
II (Zimmer, Germany) total knee arthroplasty without
resurfacing of the patella was implanted. Postopera-
tively all patients received a risk adjusted anticoagula-
tion treatment, for example, high risk patients received
Arixthra
® 1 × 1 s.c. injections over six weeks. Post-
operatively all patients were allowed for full weight
bearing. After discharge from hospital the patients
were transferred to an inpatient rehabilitation unit for
further three weeks.
Clinical Pathway Description
The study population was selected from the waiting list
for total knee arthroplasty at the trial coordinators’
Orthopedic Surgery department. Patients with severe
deformities, bone defects, prior infections, posttraumatic
disease, instabilities or revisions were not considered for
inclusion into the clinical pathway. All patients were
seen 5-7 days prior to surgery to check their medical
condition and to ensure completeness of the medical
records.
consecutive 
recruitment
3 months‘ 
individual recall
cohort 1
(pre pathway
implementation)
132 patients
cohort 2
(post pathway
implementation)
128 patients
consecutive 
recruitment
3 months‘ 
individual recall evaluation evaluation
pathway derivation
and implementation
cohort 2 B
(post pathway 
implementation)
58 patients
having attended
personal briefing
cohort 2 A
(post pathway 
implementation)
70 patients
NOT having attended
personal briefing
02/2006 08/2006 02/2007 08/2007
Figure 1 Illustration of the sequential cohort design first consecutively recruiting patients, who underwent total knee arthroplasty
(TKA) before implementation of a critical pathway on TKA, and then recruiting 128 patients, who underwent TKA after pathway
implementation (the latter being stratified for attendance of a personal briefing as a voluntary part of the pathway post-hoc during
exploratory analysis of the cohorts’ clinical data).
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invited to an information session [17]. About one
month prior to surgery the patients were informed
about their disease, the surgical procedure and the post
surgery stationary course as well as the standard rehabi-
litation process thereafter by a senior orthopedic sur-
geon (SK). Further information about anaesthesia and
the post surgical pain therapy were presented by a
senior anaesthesiologist. During the same schedule
patients were educated using crutches and physiother-
apy by a physiotherapist. Patients had the opportunity
to ask and discuss any given information as well as any
further question. The patients received a printed booklet
[18] containing information about the orthopaedic pro-
cedure and the subsuquent rehabilitation as well as an
overview scheme for their expectable “day to day pro-
gress” in hospital. The latter should explicitly level the
patients’ expectation on achievable functional and daily
life progress during the first weeks after surgery. Atten-
dance of this personal briefing session was voluntary;
each individual was personally by the local study
coordinator.
Alongside their social life circumstances the patients
were hospitalized on the day of surgery. The elderly as
well as patients living in larger distance from the depart-
ment were hospitalized at the day prior to surgery.
Further medical treatment followed standardized mile-
stones. Discharge planning was done on day one after
surgery; according the German standards the majority of
patients underwent in house rehabilitation after hospital
stay.
As a feature of the clinical pathway, “pathway
patients” were gathered into groups to have surgery on
the same day and to become hosted in the same room
(s). The team in the operation theatre was not changed
throughout the day and operated 3 - 4 pathway patients.
During the indoor post surgical rehabilitation course
physiotherapy exercises were done in the patient room
(s) within the actual group of “pathway patients” [19,20].
Patient Characteristics
The patient cohorts before and after pathway implemen-
tation showed a median age of 68 versus 69 years at the
day of surgery (64% versus 57% females, respectively).
Respective fractions of 32% versus 29% of the patients
reported to live alone, 8% versus 9% reported a regular
working employment (at least 4 hours per day) during a
six months period before surgery; 22% versus 17%
reported a higher education (academic degree, college
etc).
A sub cohort of only 58 patients attended the personal
briefing offer as part of the clinical pathway under con-
sideration (Table 1). However, the sub cohorts with and
without attendance of the briefing did not differ among
each other concerning sociodemographic characteristics
or surgical process determinants (Tables 1 and 2,
respectively); furthermore they did not differ from the
first cohort before pathway implementation.
Primary Endpoints and Evaluation Target Parameter
The primary clinical endpoint of this investigation was
the individual gain in algo-function as assessed by
means of the WOMAC osteoarthritis questionnaire: one
week before as well as three months after surgery
patients answered the 24 WOMAC items, which were
documented in terms of a five-staged ordinal scale. The
24 items were then averaged and transformed into a
scale of 0 - 100%, where the scale maximum 100% indi-
cates optimum well-being in each of the 24 items. The
intraindividual difference post - pre [%] of this trans-
formed WOMAC index was then considered as a surro-
gate for the patients’ clinical benefit achieved by TKA.
Table 1 Sociodemographic cofactors in TKA patients before and after implementation of a clinical pathway were
found comparable.
before pathway
implementation
after pathway implementation, without
personal briefing
after pathway implementation and
personal briefing
(n = 132) (n = 70) (n = 58)
age: median and range
[years]
68 (43 - 88) years 69 (46 - 85) years 70 (53 - 80) years
< 60 years 19% 20% 16%
60 - 70 years 40% 34% 40%
> 70 years 41% 46% 45%
females 64% 54% 59%
living alone 32% 30% 26%
under employment 8% 10% 9%
graduate 20% 13% 22%
distribution characteristics for sociodemographic cofactors assessed in 132 patients, who underwent total knee arthroplasty (TKA) before implementation of a
critical pathway on TKA, versus 128 patients, who underwent TKA after path implementation (the latter being stratified for attendance of a personal briefing as a
voluntary part of the pathway)
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were the total direct costs of the health care process [€]
from the Orthopedic Surgery Department’s perspective
as coordinating and cost charging health care provider
unit. Total costs were estimated by means of individual
sub process cost documentation including the following
hospital associated cost segments: anaesthesia, radiology,
laboratory, surgery, implant and associated medicinal
devices, medication costs, stationary care charges and
physiotherapy care charges. Note that this primary esti-
mation did not involve direct human ressource-related
costs for the implementation and maintenance of the
pathway by the Department members, but only direct
costs related to the patient-related intervention constitu-
ents such as the written material and the reimbursement
of personal briefing attendances.
The primary health economic target parameter of the
investigation was then the individual marginal cost
effectiveness ratio (MCER) relating a patient’s process
cost sum to his/her individual gain in algo-function as
assessed by means of the WOMAC index [€/%]. In
terms of this target parameter the clinical pathway
under consideration was considered cost efficient, as
soon as the (sub) process costs in the first cohort before
pathway implementation were found higher than in the
second cohort after implementation; furthermore, the
pathway was considered cost effective, if in addition the
WOMAC index increase in the second cohort was not
l o w e rt h a ni nt h ef i r s tc o h o r ta n d ,i na d d i t i o n ,t h e
MCERs after pathway introduction showed smaller costs
per gained benefit unit.
The confirmatory cohort comparison was based on
the MCER, where individual cost effectiveness of a
patients’ care process was defined by means of a (sub)
process cost/patient benefit relation ≤ 100 €/%
WOMAC increase. This benchmark was defined a priori
of the trial and can be motivated as follows: The
German DRG rate amounts to about 7500 € for TKA,
which can be expected to result in median WOMAC
increases of about 40%. The ratio of these median esti-
mates would then become 7500 €/40% = 188 € per
gained % increase in the WOMAC index due to TKA.
Bearing this heuristic benchmark in mind, individual
costs of 100 € per gaines WOMAC unit would corre-
spond to a quite cost efficient health care process. How-
ever, since the DRG rate covers any financial investment
from the hospital’s perspective, it corresponds to a max-
imum cost sum from the health care providers’ perspec-
tive. Bearing the above sub process components in
mind, the authors pre-calculated an expectable sub pro-
cess cost sum of 4500 €, which was hoped to reduce to
4000 € after clinical pathway implementation. The cor-
responding MCERs would become 113 € versus 100 €
per gained % WOMAC, respectively. In accordance to
these heuristic median estimates, an individual MCER
estimate ≤ 100 €/% was defined as an indication for
“individual cost effectiveness” for the respective patient’s
health care (sub) process.
Statistical Analysis and Sample Size Consideration
The confirmatory analysis of this cohort investigation
was based on an exact two-sided Fisher test at the 5%
significance level to compare the frequencies of “indivi-
dually cost effective” care between the cohorts before
and after clinical pathway implementation, it exceeds
the relative frequencies of patients showing a cost/bene-
fit relation ≤ 100 € per % WOMAC increase. In the
planning phase of the investigation, a frequency of at
least 75% individually cost effective processes was
expected before versus at least 90% after pathway imple-
mentation. To achieve a statistical power of at least 80%
in the detection of this assumed difference by means of
an exact Fisher test at the two-sided 5% level, a mini-
mum net cohort size of 113 patients had to be recruited.
Table 2 Surgical process characteristics in TKA patients before and after implementation of a clinical pathway were
found comparable.
before pathway
implementation
after pathway implementation, without
personal briefing
after pathway implementation and
personal briefing
(n = 132) (n = 70) (n = 58)
surgery performed by trial
investigator
25% 30% 22%
median duration of surgery 88 min 83 min 87 min
median duration of indoor
treatment
9 days 9 days 9 days
patients with PCCL
1 „0” 42% 60% 55%
patients with PCCL
1 „3” or
„4”
34% 27% 24%
distribution characteristics for surgical process characteristics assessed in 132 patients, who underwent total knee arthroplasty (TKA) before implementation of a
critical pathway on TKA, versus 128 patients, who underwent TKA after path implementation (the latter being stratified for attendance of a personal briefing as a
voluntary part of the pathway)
1PCCL = patient comorbidity complexicity level
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primary clinical endpoint and the MCER were described
by medians and quartiles (graphically on nonparametric
box plots, accordingly) to take account for possible sta-
tistical outliers. The description of categorical endpoints
was based on absolute and appropriate relative frequen-
cies. These methods were applied to the overall sample
as well as to sub samples. Intraindividual comparisons
were based on the description of difference distributions
for continuous endpoints and on total frequencies in
contingency tables for categorical endpoints.
The significance evaluation of intraindividual changes
in continuous endpoints was based on sign tests, sub
sample comparisons were based on pairwise Wilcoxon
two sample tests and on pairwise Fisher tests for catego-
rical endpoints. Results of these tests were summarized
in terms of p-values. Due to the rather exploratory char-
acter of the sub sample comparisons, these p-values
were not formally adjusted for multiplicity. A p-value <
0.05 therefore indicates locally significant sub sample
differences.
A multivariate re-analysis of the cost effectiveness data
was based on the MCER cutpoint 100 €/% and the cor-
responding definition of individually cost effective treat-
ment. This exploratory endpoint allowed for multiple
logistic regression modelling of simultaneous cost effec-
tiveness determinants like age, gender, working and
family state. Logistic regression modelling was per-
formed by means of Likelihood Ratio tests (foreward
selection at a local 5% significance level). All numerical
and graphical evaluations were based on the software
SPSS
® (release 12.0 for Windows
®).
Results
Cohort Comparison
The first cohort before pathway implementation showed
a median WOMAC increase of 39% (interquartile range
29 - 48%) from 41% before surgery to 83% three months
later in median versus an increase of 35% (24 - 45%)
from in median 44% to 82% in the second cohort after
pathway implementation (Wilcoxon p = 0.120). The
respective sub process sums were estimated 4303 €
(4130 - 4660 €) versus 4194 € (4039 - 4429 €; Wilcoxon
p = 0.002). Despite this locally significant decrease in
costs from the providers’ perspective, the individual
cost/benefit relation became worse after introduction of
the pathway: the median MCER in the first cohort was
estimated 108 € per gained% WOMAC index increase
(86 - 150 €/%) versus 118 €/% WOMAC gain (93 - 173
€/%) in the second cohort after pathway implementation
(Wilcoxon p = 0.367). An individual cost/benefit rela-
tion ≤ 100 €/% was found in 38% versus 30% of the
respective cohort patients (Fisher p = 0.278); accordingly
the introduction of an interdisciplinary clinical pathway
on TKA did not significantly change the fraction of indi-
vidually cost effective treatment courses from the health
care providers’ perspective in terms of this primary cost
effectiveness parameter.
Sub Cohort Analysis
Stratification of the second patient cohort after pathway
implementation further illustrated the above tendency
(Table 3): patients who additionally attended the volun-
tary preoperative patient information/education (n =
58), showed a median WOMAC change of 30% (21 -
Table 3 WOMAC index and sub process cost sum distributions {€] for TKA changed after the introduction of a clinical
pathway.
before pathway
implementation
after pathway implementation,
without personal briefing
after pathway implementation,
including personal briefing
(n = 132) (n = 70) (n = 58)
WOMAC index before surgery [%] 41%
(32; 48%)
44%
(34; 50%)
46%
(39; 54%)
WOMAC index three months after surgery
[%]
83%
(68; 91%)
82%
(74; 91%)
83%
(66; 90%)
intraindividual three months change in
WOMAC [%]
39%
(27; 48%)
range -20; 69%
38%
(30; 47%)
range -6; 68%
30%
(21; 45%) rrange +1; 71%
sub process cost sum [€] 4303 €
(4130; 4660 €)
4149 €
(3980; 4443 €)
4244 €
(4097; 4412 €)
individual cost effectiveness ratio [€/%
WOMAC change]
108 € /%
(86; 150 €/%)
110 € /%
(88; 145 €/%)
135 € /%
(102; 211 €/%)
individual effect costs [% WOMAC change/
1000 €process cost investment]
9%/1000 €
(6; 11%/1000€)
9%/1000 €
(7; 11%/1000€)
7%/1000 €
(5; 10%/1000€)
medians and quartiles for the total WOMAC osteoarthritis index [%, 100% = optimum rating] before and three months after total knee arthroplasty (TKA) as well
as intraindividual post - pre change [%] of the index, sub process cost sum {€] for TKA from the hospital’s perspective as well as individual ratios between the
latter (cost effectivemess, [€/%] and effect costs [%/1000 € investment], respectively), assessed in 132 patients, who underwent TKA before implementation of a
critical pathway on TKA, versus 128 patients, who underwent TKA after path implementation (the latter being stratified for attendance of a personal briefing as a
voluntary part of the pathway)
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versus a median increase of 38% (30 - 47%) from 44% to
82% among patients without patient information/educa-
tion (n = 70). The sub cohort of patients having
attended a personal briefing, as part of the implemented
clinical pathway, significantly differed from the first
patient cohort before pathway implementation (median
WOMAC increase 39%, Wilcoxon p = 0.029).
T h es u bc o h o r t sa f t e rp a t h w a yi m p l e m e n t a t i o n
showed median process cost sums of 4149 € (3980 -
4430 €, without briefing) versus 4244 € (4097 - 4412 €,
with briefing; Wilcoxon p = 0.230) and median MCERs
of 110 € versus 135 € per gained% WOMAC increase
(Wilcoxon p = 0.013). According to the locally signifi-
cant difference in clinical outcome, the sub cohort of
patients who attended the patient information/education
significantly differed from the first cohort before path-
way implementation concerning the cost/benefit relation
(Wilcoxon p = 0.005), but not concerning the process
cost sum (Wilcoxon p = 0.074). The sub cohort of
patients without patient information/education, how-
ever, showed a locally significant cost reduction (median
cost sums 4149 € versus 4303 €, Wilcoxon p = 0.001) in
comparison to the first cohort before pathway imple-
mentation, but no difference concerning clinical out-
come (median WOMAC increase 38% versus 39%,
Wilcoxon p = 0.650). The latter cohorts did not signifi-
cantly differ in individual cost effectiveness (median
MCER 110 € versus 108 € per gained% WOMAC
increase, Wilcoxon p = 0.936).
Accordingly, in terms of the primary endpoint of this
evaluation, the sub cohorts with and without attendance
to the pathway-associated briefing showed 36% versus
23% individually cost effective patient courses (indivi-
dual MCER ≤ 100 €/%); however; the two sub cohorts
after pathway implementation did not signficantly differ
in this primary cost effectiveness endpoint (Fisher p =
0.166).
Multivariate Analysis
Logistic regression modelling of the exploratory end-
point “individual MCER < 100 €/% WOMAC increase”
confirmed the dominating sub cohort impact on the
cost effectiveness outcome: neither age, gender nor
working or family state of the patients were found to be
significantly associated with the occurrence of individu-
ally cost effectiveness in terms of an MCERs ≤ 100 €/%
(Likelihood Ratio p = 0.200, p = 0.675, p = 0.730 and p
= 0.205, respectively). However, in contrast to the uni-
variate findings, no statistical signficance of the sub
cohort affiliation could be reproduced by logistic regres-
sion modelling of this binary cost effectiveness endpoint
(Likelihood Ratio p = 0.493 for the contrast between the
first cohort before and the briefed sub cohort after
pathway implementation, p = 0.705 for the correspond-
ing contrast between the respective sub cohorts after
pathway implementation with and without briefing).
The only putative explaining variable, which was
found significantly associated with the binarized MCER
endpoint, was the patients’ preoperative assessment of
their algo-functional status (Likelihood p < 0.001 for the
preoperative WOMAC index). This impact of the preo-
perative WOMAC level corresponds to the univariate
cohort gradient in median preoperative WOMAC levels
(41% before versus 44% and 46% after pathway imple-
mentation). It is illustrated by Table 4: patients with a
preoperative WOMAC index > 40% showed individually
cost effective process courses in terms of an MCER ≤
100 €/% in 52% (first cohort) versus 56% and 47% (sub
cohorts without and with briefing after pathway imple-
mentation, respectively). In summary, the observed sub
cohort difference in cost effectiveness can be explained
as an epi-phenomenon of a preoperative gradient in
algo-functional status among the respective cohorts.
Note, however, that the goodness of model fit was only
moderate for these evaluations with an overall Nagelk-
erke coefficient of only 68%.
Discussion
This study intended to evaluate the effects of a clinical
pathway for total knee arthroplasty in terms of patient-
related (self-reported) daily life function and process cost
profiles from the health care providers’ perspective by
means of a prospective pre-post cohort evaluation. In
summary, the introduction of an interdisciplinary clinical
pathway did not increase patient related outcomes in
terms of the confirmatory outcome assessment
(WOMAC total index); on the contrary, during univari-
ate confirmatory analysis the cost effectiveness from the
health care providing Orthopedic Surgery Department’s
perspective was even found reduced. By means of multi-
ple logistic regression analysis, the underlying cohort dif-
ference in cost effectiveness could be partially explained
as an epi-phenomenon of a preoperative gradient in algo-
functional status among the respective cohorts before
and after pathway implementation; it may therefore be
considered as having arisen from a somewhat asymmetric
regression to the mean effect within the sub cohorts due
to a slight (non significant) sub cohort difference in the
preoperative WOMAC scores. Nevertheless, the recently
(13) well-emphasized positive effect of clinical pathways
on both economic and clinical outcome parameters
could not be reproduced within the above sequential
cohort design investigation.
Design Considerations
The sequential cohort design was considered as an alter-
native to a (cluster) randomized trial on the effect of the
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duction of a “pre-pathway” cohort and a “pathway
cohort” within the same department will hardly be pos-
sible due to uncontrollable mechanisms of cohort inter-
actions and thereby improvement of process quality in
the “pre-pathway” cohort in the direction of the pathway
under investigation. A severely biased cohort difference
(if any) would be the result of such a randomized inves-
tigation, i.e. the benefit of its higher evidence level shall
become crucially reduced by these sources of bias. The
same holds for parallel (cluster randomized) cohorts,
which would afford involvement of several Orthopedic
Surgery departments to avoid the bias mentioned above.
Such a trial design, however, might introduce severe
bias due to the locally differing surgical investigators
within the trial sites’ pathway realisations. The observed
“pre-” versus “post-pathway” difference would then
become confounded by cofactors rather related with the
local orthopedic surgeons and their implant preferences
than with the underlying pathway proposals. In sum-
mary, despite its inferior level of evidence, the sequential
cohort design was considered less biased for the recent
research intention.
Note, however, that the design at hand may have
introduced a different kind of bias due to the choice
of time for the main intervention: the clinical pathway
proposal under consideration mainly concentrates on
patient-related information by means of written mate-
rial and personal briefing; it thereby addresses the
area of patient compliance and awareness. As a matter
of fact, this central part of the intervention was imple-
mented before (!) the preoperative WOMAC assess-
ment of the post pathway cohort, i.e. the preoperative
functional assessment of this post-intervention cohort
may have been biased in contrast to the corresponding
ratings in the pre-intervention cohort. This bias may
then also have been introduced into the marginal cost
effectiveness estimates and thereby into the primary
endpoint evaluation. On the other hand, Table 3 indi-
cates, that all three sub cohorts showed comparable
preoperative median WOMAC scores (not differing
locally significantly), with preoperative medians
increasing proportionally to the amount of individually
achieved information. Whether this gradient in preo-
pative index distributions is rather an indication of
intervention-related bias in the above meaning or
rather represents a consequence of different recruite-
ment patterns among the pre and post pathway imple-
mentation cohorts (related to the willingness to attend
briefings) cannot be quantified by means of the data
at hand.
Furthermore, one must critically discuss the fact that
the attendance of the personal briefings as a central
constituent of the pathway intervention was held volun-
tary: note that only 58 out of 128 patients accepted this
offer and thereby put the pathway under consideration
into question! This could have been and, in fact, was
expected during the planning phase of the investigation
with regard to the patients age, clinical and socioeco-
nomic status: note that TKA patients usually will
require the help of relatives (to provide a lift etc) to
attend personal briefing schedules. Nevertheless, we
found it unethical to force our trial participants to
attend the briefings “by all means” (which, in addition,
might again have introduced severe bias into recruite-
ment patterns and preoperative ratings!).
Table 4 Individual cost effectiveness ratios alongside a critical pathway on TKA are associated with algo-functional
status before surgery
individual cost
effectiveness
individual cost
effectiveness
WOMAC index [%] before
TKA
≤100 €/% > 100 €/%
before pathway implementation
≤ 40% 25% 75%
> 40% 52% 48%
after pathway implementation, without personal
briefing
≤ 40% 24% 76%
> 40% 56% 44%
after pathway implementation and personal briefing
≤ 40% 13% 87%
> 40% 47% 53%
relative frequencies of individual cost effectiveness ratios ≤ 100 €/% between partial cost sum {€] from the hospital’s perspective and three months WOMAC
change after TKA [%], assessed in 132 patients, who underwent TKA before implementation of a critical pathway on TKA, versus 128 patients, who underwent
TKA after path implementation (the latter being stratified for attendance of a personal briefing as a voluntary part of the pathway), stratified for the patients’
total WOMAC osteoarthritis index before surgery [„≤ 40%” versus „> 40%"]
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The interdisciplinary conception of the clinical pathway
for TKA was based on medical records and data from
an initial prospective cohort [1,2]. Prior to this study the
treatment for total hip arthroplasty was organized by
means of a clinical pathway by the same Orthopaedic
Surgery department. As a potential side effect of the
resulting pathway experience within the overall depart-
ment, the first TKA cohort ("pre-pathway”)a l r e a d y
underwent rather elaborate standards, which may have
implicitly arisen from the previous THA pathway
experience: for example, all patients undergoing total
joint arthroplasty were seen 5-7 days prior to surgery to
check the medical condition and the completeness of
medical records; furthermore their LOS was standar-
dized and optimized. As a putatively implicit conse-
quence, median and quartile length of stay for total
knee arthroplasty patients were both already reduced to
9d a y si nt h ef i r s tc o h o r tb e f o r ee x p l i c i td e f i n i t i o na n d
implementation of the TKA critical pathway. Bearing
these initial conditions in mind, the rather moderate
effect of the above pathway introduction on process
characteristics such as LOS becomes motivated by the
following facts from literature:
a) failing of improvement in cost effectiveness for
patients undergoing TKA was also found in other
studies [21,22]
b) like in our study no further improvement in
patient-related outcome was found after accelerated
intervention [22]
c) the potential of clinical pathways to show sequen-
tial improvement in patient care and cost reduction
seems obviously limited, as quantified by Vanhaecht
by means of repeated observations of sequentially
modified TKA pathways [11,14]
In this sense the previous implementation of a clinical
pathway for total hip arthroplasty in the investigators’
hospital might already have implied an implicit pathway
optimization onto TKA processes as well, before any
“pre-pathway” data documentation was started in the
first cohort. In summary the main interventional consti-
tuents of the clinical pathway under consideration here
were “patient information/education”, “grouping of
patients during physiotherapy and hospital stay”, “secur-
ing the treatment safety with milestones and discharge
planning” and, in particular, “leveling patient expectation
by explaining expectable postoperative day-to-day pro-
gress” as well as “preoperative training in the postopera-
tive use of walking aids”. No interventions concerning
the implant were made. All patients received the same
implant at the same costs [9,23].
The observed total order improvement in the
WOMAC score for patients undergoing total knee
arthroplasty is comparable to other studies [9,23-26].
Nevertheless, the somewhat smaller median increase in
the second sub cohort (median increase 30% versus 39%
and 38% in the other sub cohorts, respectively), affords
critical consideration: the patient information/education
were offered to all patients of the second cohort. The
sub cohort of patients, who accepted these offers was
found higher educated and showed an overall better
medical condition as compared to the cohort refusing
this offer (Tables 1 and 2). The baseline WOMAC index
of the latter sub cohort was found higher, but its three
months WOMAC index ended at the same level than
did the other cohort’s median index. As a consequence
the median intraindividual WOMAC changes turned
out smaller for the “highly informed” sub cohort. It is
yet unclear whether this effect is a result of the informa-
tion offer and an increased expectation within the
informed sub cohort [27] or rather a patient-associated
selection bias in the direction of a better preoperative
health condition (Table 2) as a surrogate of the ability
to attend the personal briefings.
Economic Considerations
The screened costs from the health care providers’ per-
spective were found significantly lower in the second
cohort. In contrast to other studies this cost reduction
was not achieved by shortening the length of stay or
change in implant selection [8,9,11,28,29]: consideration
of the cost components indicated that grouping of
patients for physiotherapy had contributed the main
part to the observed overall cost reduction. In contrast
to this observation, most authors found maximum cost
reduction from the health care providers’ perspective by
reducing or at least standardizing the LOS: the potential
to show an improvement in cost-effectiveness by imple-
mentation of critical pathways depends on the initial
medical treatment. However, our initial LOS for patients
undergoing total knee arthroplasty appears to be short
compared to the German population of patients under-
going TKA and other European groups [11,30]. As a
consequence from both an ethical and clinical point of
view, the clinical project investigators were - with
respect to patient safety - unwilling and unable to
implement a further shortening in LOS, and thereby the
individual cost effectiveness ratios turned out merely
unchanged for the cohort, who refused the offered
patient information/education.
On the other hand the variation in observed process cost
sums declined for this cohort, which indicates an intrinsic
benefit of the pathway implementation in terms of process
costs as one main target in clinical pathways [31].
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reduction after pathway implementation in mind, a dif-
ferent source of human resources related costs must be
critically discussed: the above presentation primarily
considered direct process costs for health care from the
hospital’s perspective, which meant concentration on
investment for treatment and care as well as on human
resources necessary to provide the latter. A future stage
of this evaluation will concentrate on a cost-cost analy-
sis and estimate the human resource investment for
conception, implementation and maintenance of the cri-
tical pathway itself. As a broad initial estimation the lat-
ter will amount to not less 25.000 € per year and
pathway (and certainely more during the conception
and implementation phase), and will thereby crucially
reduce the nominal cost reductions described above.
Conclusions
In terms of a cost-cost balance, surgical department
coordinators may feel warned, that the implementation
of critical pathways presents an investment into quality,
but - at least after already having achieved a certain
stage of process quality - may not necessarily result in
cost reduction, but can even end up in increased
human resource investment. Furthermore one should
note, that it cannot be avoided that a critical pathway
will involve more of less specific local conditions, which
will make it more explicit and easier to apply for local
residents, but require immediate and dynamic changes
of the pathway as soon as these local conditions change
or are being changed: if, for example, local physiother-
apy staff is no longer directly available due to structural
changes in the overall hosting University Hospital, the
less direct accessibility of physiotherapy within the criti-
cal pathway’s course may require its complete
redesigning.
To our understanding a clinical pathway will not serve
as a “magic wand” to induce unlimited improvement in
quality of care and cost saving. Clinical pathways repre-
sent a management tool to organize and optimize
patient care by assuring maximum possible and consis-
tent medical quality and cost containment. Within
already optimized or at least well-organized medical cir-
cumstances a clinical pathway is unable to further
improve the cost-effectiveness of treatment courses.
Nevertheless, pathway screening and maintenance as a
tool of continuous quality management can still be used
to ensure the achieved level of medical and economic
process and outcome quality.
Further research on this topic is certainly needed
[14,15,31], in particular with regard to the increasing
number of patients awaiting TKA and THA within the
forthcoming decades.
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